 |
|
August 14, 2008
Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
FAIRFIELD, N.J., Aug. 14, 2008 -- Arno Therapeutics, Inc.
(OTC Bulletin Board: ARNI), a clinical-stage biopharmaceutical company focused
on oncology, today announced the appointment of Brian Lenz, CPA, as its Chief
Financial Officer. Mr. Lenz brings over 10 years of financial and operational
management experience in addition to significant experience in capital raising
and M&A activities.
"We are very pleased to have someone with Brian's broad financial and
public markets experience join our team," said Scott Z. Fields, MD, President
and Chief Medical Officer of Arno. "We look forward to working with him as we
continue to grow and expand our operations."
Prior to joining Arno Therapeutics, Mr. Lenz was Chief Financial Officer
and Treasurer of VioQuest Pharmaceuticals, Inc. since 2004, and prior to that
served as the company's controller from 2003 to 2004. At VioQuest, Mr. Lenz
was responsible for the financial and operational reporting, as well as
capital raising and M&A activities. Prior to VioQuest, Mr. Lenz was a
controller with Smiths Detection Group from 2000 to 2003. Before joining
Smiths, Mr. Lenz was a senior auditor with KPMG, LLP from 1998 to 2000. Mr.
Lenz holds a BS in Accounting from Rider University and received his MBA from
Saint Joseph's University. He is a certified public accountant licensed in the
State of New Jersey.
About Arno Therapeutics
Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that
develops and commercializes innovative products for the treatment of cancer
patients. Arno's lead compound is AR-67, a novel, third-generation
camptothecin analogue in Phase I studies in patients with advanced solid
tumors that has demonstrated high potency and significantly improved
pharmacokinetic properties when compared with marketed second-generation
products in its class. Arno is also developing two pre-clinical compounds.
AR-12 is a potential first-in-class, orally available PDK1 inhibitor that
blocks the PI3K/Akt pathway undergoing IND-enabling studies. AR-42 is an
orally available, targeted inhibitor of the Pan-DAC and Akt pathways also
undergoing IND-enabling studies. Arno is actively pursuing additional
compounds to expand its portfolio. For more information on Arno please visit
www.arnothera.com.
Contact:
Brian Lenz, CPA
Chief Financial Officer
Arno Therapeutics, Inc.
(862) 703-7175
bl@arnothera.com
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve
substantial risks and uncertainties. All statements, other than statements of
historical facts, included in this press release regarding our strategy,
future operations, outlook, milestones, the success of Arno's product
development, future financial position, future financial results, plans and
objectives of management are forward-looking statements. We may not actually
achieve these plans, intentions or expectations and Arno cautions investors
not to place undue reliance on our forward-looking statements. Actual results
or events could differ materially from the plans, intentions and expectations
disclosed in the forward-looking statements we make. Various important factors
that could cause actual results or events to differ materially from the
forward-looking statements that we make are described in greater detail in the
reports we file with Securities and Exchange Commission, including those
described under the caption "Risk Factors" in our Current Report on Form 8-K
filed with the Securities and Exchange Commission on June 9, 2008. Arno is
providing this information as of the date of this press release and does not
undertake any obligation to update any forward-looking statements as a result
of new information, future events or otherwise. |
